Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 16
278
Views
2
CrossRef citations to date
0
Altmetric
Short Communications

Antileishmanial and lung adenocarcinoma cell toxicity of Withania somnifera (Linn.) dunal root and fruit extracts

ORCID Icon, , , , , , & show all
Pages 4231-4237 | Received 27 Feb 2021, Accepted 18 Aug 2021, Published online: 14 Sep 2021

References

  • Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. and WHO Leishmaniasis Control Team. 2012. Leishmaniasis worldwide and global estimates of its incidence. PloS One. 7(5):e35671.
  • Barta JA, Powell CA, Wisnivesky JP. 2019. Global epidemiology of lung cancer. Ann Glob Health. 85(1):1–16.
  • Bolleddula J, Fitch W, Vareed SK, Nair MG. 2012. Identification of metabolites in Withania sominfera fruits by liquid chromatography and high-resolution mass spectrometry . Rapid Commun Mass Spectrom. 26(11):1277–1290.
  • Callahan HL, Portal AC, Devereaux R, Grogl M. 1997. An axenic amastigote system for drug screening. Antimicrob Agents Chemother. 41(4):818–822.
  • Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. 2013. An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int. 62(3):253–261.
  • Chandrasekaran S, Veronica J, Sundar S, Maurya R. 2017. Alcoholic fractions F5 and F6 from Withania somnifera leaves show a potent antileishmanial and immunomodulatory activities to control experimental visceral leishmaniasis. Front Med (Lausanne)). 4:55.
  • Chatterjee S, Srivastava S, Khalid A, Singh N, Sangwan RS, Sidhu OP, Roy R, Khetrapal CL, Tuli R. 2010. Comprehensive metabolic fingerprinting of Withania somnifera leaf and root extracts. Phytochemistry. 71(10):1085–1094.
  • Dom M, Vanden Berghe W, Van Ostade X. 2020. Broad-spectrum antitumor properties of Withaferin A: A proteomic perspective. RSC Med Chem. 11(1):30–50.
  • Ephros M, Waldman E, Zilberstein D. 1997. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother. 41(5):1064–1068.
  • Grover A, Katiyar SP, Jeyakanthan J, Dubey VK, Sundar D. 2012. Blocking protein kinase C signalling pathway: mechanistic insights into the antileishmanial activity of prospective herbal drugs from Withania somnifera. BMC Genom. 13(S7):1–11.
  • Gupta A, Singh S. 2014. Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharm Biol. 52(3):308–320.
  • Kaur S, Chauhan K, Sachdeva H. 2014. Protection against experimental visceral leishmaniasis by immunostimulation with herbal drugs derived from Withania somnifera and Asparagus racemosus. J Med Microbiol. 63(Pt 10):1328–1338.
  • Lopresti AL, Smith SJ. 2021. Ashwagandha (Withania somnifera) for the treatment and enhancement of mental and physical conditions: A systematic review of human trials. J. Herb. Med. 28:100434.
  • Mehrotra V, Mehrotra S, Kirar V, Shyam R, Misra K, Srivastava AK, Nandi SP. 2011. Antioxidant and antimicrobial activities of aqueous extract of Withania somnifera against methicillin-resistant Staphylococcus aureus. J Microbiol Biotechnol Res. 1(1):40–45.
  • Mondal S, Mandal C, Sangwan R, Chandra S, Mandal C. 2010. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cancer. 9(1):239.
  • Murakami Y, Kawata A, Suzuki S, Fujisawa S. 2020. Radical-scavenging and pro-/anti-inflammatory activity of tetracycline and related phenolic compounds with or without visible light irradiation. In Vivo. 34(1):81–94.
  • Ng QX, Loke W, Foo NX, Tan WJ, Chan HW, Lim DY, Yeo WS. 2020. A systematic review of the clinical use of Withania somnifera (Ashwagandha) to ameliorate cognitive dysfunction. Phytother Res. 34(3):583–590.
  • Nibret E, Wink M. 2011. Trypanocidal and cytotoxic effects of 30 Ethiopian medicinal plants. Z Naturforsch C J Biosci. 66(11-12):541–546.
  • O'Keeffe A, Hyndman L, McGinty S, Riezk A, Murdan S, Croft SL. 2019. Development of an in vitro media perfusion model of Leishmania major macrophage infection. PloS One. 14(7):e0219985.
  • Orabi MAA, Zidan SA, Attia GH, Alyami HS, Matsunami K, Hatano T. 2020. Ellagitannins and simple phenolics from the halophytic plant Tamarix nilotica. Nat Prod Res. 2:1–9.
  • Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, Pountain AW, Mwenechanya R, Papadopoulou B. 2017. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 11(12):e0006052.
  • Rai M, Jogee PS, Agarkar G, Santos CAD. 2016. Anticancer activities of Withania somnifera: Current research, formulations, and future perspectives. Pharm Biol. 54(2):189–197.
  • Rasool M, Varalakshmi P. 2006. Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: An in vivo and in vitro study. Vascul Pharmacol. 44(6):406–410.
  • Raut AA, Rege NN, Tadvi FM, Solanki PV, Kene KR, Shirolkar SG, Pandey SN, Vaidya RA, Vaidya AB. 2012. Exploratory study to evaluate tolerability, safety, and activity of Ashwagandha (Withania somnifera) in healthy volunteers. J Ayurveda Integr Med. 3(3):111–114.
  • Sikandan A, Shinomiya T, Nagahara Y. 2018. Ashwagandha root extract exerts anti‑inflammatory effects in HaCaT cells by inhibiting the MAPK/NF‑κB pathways and by regulating cytokines. Int J Mol Med. 42(1):425–434.
  • Tandon N, Yadav SS. 2020. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. J Ethnopharmacol. 255:112768.
  • Trivedi MK, Panda P, Sethi KK, Jana S. 2017. Metabolite profiling in Withania somnifera roots hydroalcoholic extract using LC/MS, GC/MS and NMR spectroscopy. Chem Biodivers. 14(3):e1600280.
  • Walker DM, Oghumu S, Gupta G, McGwire BS, Drew ME, Satoskar AR. 2014. Mechanisms of cellular invasion by intracellular parasites. Cell Mol Life Sci. 71(7):1245–1263.
  • Zur E. 2019. Topical treatment of cutaneous leishmaniasis in Israel, Part 1. Int J Pharm Compd. 23(3):200–207.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.